Hematologist/Oncologist and @nyulisom_hemonc Fellowship Program Director @nyulangoneli #hemeonc #multiplemyeloma #myeloma #mmsm #lymphoma. Tweets are my own.
In #myeloma, why do we perform an SPEP using serum and not plasma? Serum = plasma minus clotting factors. A plasma protein electrophoresis (show below) might obscure a monoclonal protein due to clotting factors such as fibrinogen. (Ref: Clinical Immunology 3rd Ed, Chapter 96)
Here are the top 11 abstracts and (all were scored fairly) at #ASH2026 that I believe will show main impact :
1. AQUILA · Abstract #112 · 9.8/10
1/3 Does treating high-risk smoldering myeloma help patients live longer? My #1 #ASH26 abstract is AQUILA (#112), daratumumab vs active monitoring in high-risk SMM. My score: 9.8/10.
2/3 Among 390 randomized patients, 7-year overall survival was 87.8% with daratumumab vs 78.7% with monitoring. That’s a 9.1-point absolute difference. Median PFS was 82.5 vs 34.9 months.
3/3 This changes my conversation with an asymptomatic patient. Once we confirm high-risk SMM and exclude active myeloma, we can weigh up to 3 years of treatment against a measurable survival benefit.
#mmsm#myeloma#USMIRC#MedEd#medtwitter@USMIRCNEWS@US_HMC@Larvol@OpenMedKate@oncodaily
My top @ASH_hematology#ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm@utswcancer
1⃣MonumenTAL-6: Tec+Tal and Tal+Pom vs EPd/PVd ➡️Phase III, RRMM after 1–4 prior lines, all exposed to anti-CD38 and lenalidomide (80% anti-CD38-refractory)
➡️n=838; median FU: 13.4 mo
➡️Tec+Tal improved PFS HR 0.11; 12-mo PFS 89% vs 30%) and OS (HR 0.38; 12-mo OS 91% vs 80%). Tal+Pom also better than control arm (PFS HR 0.27, OS HR 0.55).
🛑Grade 3/4 infections were 312% with Tec+Tal vs 25% with control (92% of patients needed IVIG), ICANS 6%, taste changes 76% and weight loss 41% (Only 6% stopped treatment for AEs)
Time limited therapy with dual targeting in pts after anti-CD38/len failure
#Myeloma Paper of the Day: Modeling of long-term PFS in NDMM treated w/ Dara-VRd on PERSEUS (TE pts) finds 158-255 months (VRd 76-119 mos) while for CEPHEUS (TIE pts) projected median PFS range across distributions was 96-118 (VRd 52-54 mos): pubmed.ncbi.nlm.nih.gov/4300…. #mmsm
How do we assess fitnes for cellular therapies for hematologic malignancies? Great working with Dr. Marco Ruiz and @ASTCT on this article:
astct.org/Nucleus/Article/be…
Join us tonight for the Long Island @BloodCancerUtd annual Light the Night walk to support research for those affected by blood cancers. @Perlmutter_CC will have a table with lots of giveaways and swag. Hope to see you there!
Fundraising team: pages.lls.org/ltn/li/Eisenho…
Nearly half of patients with CLL develop a serious infection, and infection contributes to almost a third of deaths. Danielle M. Brander, MD, and Marc J. Braunstein, MD, PhD, on why that risk should shape frontline therapy choice.
Explore the OncLive® News Network series: hubs.li/Q04Br9wf0@dbranderMD@DukeHealth@docbraunstein@NYULISOM_HemOnc#leusm#CLL
Annual MRD testing is now in the NCCN myeloma guidelines.
Recent version 1.2027 lays out bone marrow MRD by NGS (FDA-approved assay) or multicolor flow across the whole course of treatment: after induction, at 100 days or 3 months after transplant or CAR-T, after relapse therapy or a major Tx change, and at regular intervals during maintenance or surveillance. 10^-6 is preferred, 10^-5 is the minimum. A baseline clonotype sample goes in once, at diagnosis or before Tx. And the line that will change clinic workflow: "annual testing is the general recommendation."
Quick thoughts
- Sustained MRD negativity tells us far more than a single negative result, and you can't know it's sustained without serial testing
- The baseline clonotype sample is the step most likely to get missed. If nobody sends it at diagnosis, NGS tracking gets much harder later, often waiting on a relapse sample. That's an operational fix: build it into the diagnostic marrow order set
- For EMD, PCL and oligo- or non-secretory disease, MRD supplements imaging (and circulating plasma cells in PCL) rather than replacing it. Good that this is spelled out
- A marrow every year is real burden for pts, and for practices that don't have a procedure slot or a payer who agrees
- The bigger gap is translational. We have a schedule for measuring MRD, but outside trials we still don't have validated rules for what to do with the result: when to stop maintenance, when to escalate on MRD resurfacing
An important step in right direction, but much more to do for implementing in beyond academic practices.
#MultipleMyeloma#mmsm#MRD
Thanks @montypal@ASCO for inviting us!
Sure, @docbraunstein and I started by talking BsAb & CAR-T sequencing… but soon we touched on:
1️⃣ de-escalation trials - who, how, and when?
2️⃣ community-academic partnerships
3️⃣ #downwithdex mouthwash with talquetamab; more at #ASH26!
Nice to see the subgroup analysis we published recently in CEPHEUS for transplant ineligible #myeloma. Continuing to improve outcomes in MM. @Perlmutter_CC
PERSEUS long-term follow-up at #IMS26: D-VRd → DR vs VRd → R in transplant-eligible NDMM (median follow-up >80 mo)
💡72-mo PFS: 81% vs 56%
💡Median PFS: not reached vs 80 mo
💡The benefit held across risk groups:
🟢 Standard risk: 88% vs 63% (HR 0.27)
🔴 High risk: 55.0% vs 33% (HR 0.55)
💡MRDneg ~60-65% at 2 yr and 3 yr
Exceptional outcomes with QUADs, highlighting potential to stop maintenance for standard risk at 2yrs. High-risk MM still needs better options #IMS26@Myeloma_Society